CMAG: Development Cellular Models of the Ear and Nose to Study the Mechanisms of Hearing
Sponsor
University Hospital, Brest (Other)
Overall Status
Recruiting
CT.gov ID
NCT04823195
Collaborator
(none)
30
1
24
1.3
Study Details
Study Description
Brief Summary
Development of cells culturesissued from Nose and Ear to study auditory mecanisms.
Study of the cis-Modulation of the gene GJB2 for the patients with early presbycusis to identify the genetic cause of hearing loss.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of Cellular Models of the Ear and Nose From Patient Samples to Study the Mechanisms of Hearing
Actual Study Start Date
:
Jun 15, 2021
Anticipated Primary Completion Date
:
Jun 15, 2023
Anticipated Study Completion Date
:
Jun 15, 2023
Outcome Measures
Primary Outcome Measures
- GJB2 cis regulation [2 years]
Culture cell model
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Hearing loss Presbycusis Exostosis
Exclusion Criteria:
- Genetic hearing loss
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHRU de Brest | Brest | France | 29609 |
Sponsors and Collaborators
- University Hospital, Brest
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT04823195
Other Study ID Numbers:
- CMAG (29BRC20.0331)
First Posted:
Mar 30, 2021
Last Update Posted:
Jun 30, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: